PTC Therapeutics (PTCT) Q3 2026 earnings review
PTC raises its sales outlook as Sephience expands overseas
PTC Therapeutics, a maker of rare-disease medicines, is growing fast on its new metabolic drug Sephience while buying a second act. Product sales more than doubled from a year ago as Sephience reached $182 million, helped by overseas expansion and another Russian state order for its older drug Translarna. Chief executive Matthew B. Klein raised the full-year product outlook by $75 million at the middle, though a $111 million upfront charge to buy the Fabry disease gene therapy ST-920 pushed the company into a $52 million net loss.
| Product revenue | $275.9M +111% from a year ago |
|---|---|
| Sephience revenue | $181.9M +20% from last quarter |
| Active Sephience patients | Over 2,000 1,647 last quarter |
| Full-year product outlook | Raised $75M middle of the range: $975M (+66%) |
⚖️ Verdict: 🟢 Bullish
The story got better because overseas Sephience demand jumped 56% from last quarter and the ST-920 purchase gives PTC a second potential launch in 2027, easing single-drug risk. Two cautions remain: revenue per average Sephience patient fell for a third straight quarter to about $100,000 by our math, and the raised full-year outlook still implies a 15% product sales drop in the fourth quarter.
The question now is whether falling revenue per Sephience patient is just temporary international mix or a lasting price drag as European rebates take hold. If overseas early-access patients convert to full commercial prices without a steep German discount, revenue will catch up to the 2,000-patient base; if rebates bite, patient counts will keep outrunning sales. The German reimbursement decision and fourth-quarter revenue per patient will settle it.
🐂 Bull Case
Sephience Growth Outruns the Raised Plan
Sephience, PTC's daily pill for the genetic metabolic disorder phenylketonuria (PKU), is carrying the business one year into its rollout. "Now at the one-year mark, the launch has been a success by all measures," chief executive Matthew B. Klein said. Overseas sales are now the fastest-growing piece as early-access programmes expand across Europe, Latin America and Japan.
- Sephience total revenue: $181.9 million, up 20.2% from last quarter
- US Sephience revenue: $145.0 million, up 13.7% from last quarter by our math
- International Sephience revenue: $37.0 million, up 55.7% from last quarter by our math
- Full-year product revenue outlook: raised $75 million at the middle of the range to $960–990 million
Management raised the full-year product outlook for a third straight quarter, but the new range still looks cautious. Because nine-month product sales already sit at $740.3 million, the middle of the new plan leaves $234.7 million for the fourth quarter by our math. That implies a 14.9% drop from the third quarter, even though Sephience just added at least 353 net new patients.
What to watch: fourth-quarter international Sephience revenue when full-year results arrive in February. Another jump above $45 million would show overseas demand can keep lifting total sales even before European pricing talks finish.
Gene Therapy Deal Cuts Single-Drug Risk
Investors have worried that the rare-disease drugmaker relies too heavily on Sephience, which now brings in 65.9% of product sales as older muscular dystrophy medicines shrink. On the other hand, PTC holds over $2.1 billion in cash and promised to buy new medicines without taking on heavy debt. This quarter it bought ST-920, a treatment for the inherited enzyme disorder Fabry disease, from Sangamo Therapeutics.
The company paid $111.0 million upfront and agreed to pay up to $100.0 million more if the drug wins US regulatory approvals. PTC describes ST-920 as "a one-time administered AAV gene therapy with the potential to reduce the burden associated with chronic enzyme replacement therapy". It plans to complete its US approval filing in the fourth quarter, which could bring an accelerated approval and commercial launch in 2027.
What to watch: confirmation that the Food and Drug Administration accepts the ST-920 filing in early 2027. Acceptance under priority review would give the group a second commercial growth driver before the end of next year.
Early Trials Advance on Schedule
Beyond Sephience, the New Jersey biotech wants to prove its drug-discovery engine can build a broader pipeline. Management met two third-quarter clinical deadlines it set earlier this year. It started the PROVE-FA trial for vatiquinone, a medicine for the nerve disorder Friedreich's ataxia that the FDA rejected last year. That global study will enrol about 120 patients aged 7 to 21 and compare them against untreated historical records.
The drugmaker also started a mid-stage study for PTC844, an oral immune-system blocker, and kept advancing PTC303, a gene-splicing drug candidate aimed at entering human trials in 2027. Meanwhile, partner Novartis is enrolling roughly 770 Huntington's disease patients into the late-stage INVEST-HD trial for votoplam.
What to watch: enrolment completion in the 120-patient PROVE-FA trial during 2027. Fast enrolment would keep the vatiquinone refiling on track without requiring large new research budgets.
🐻 Bear Case
One-Off Charges and Non-Cash Royalties Mask Cash
"We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year," Klein said. Testing that claim is hard because the press release omits a cash flow statement, and a large slice of reported revenue brings in no cash.
- Evrysdi royalty revenue: $81.7 million (22.8% of total revenue), all passed to Royalty Pharma
- Acquired research charge for ST-920: $111.0 million, or 31.0% of revenue
- Loss on paying off debt: $19.3 million, alongside $45.9 million of net interest expense
- Cash and marketable securities: $2,127.9 million, down $101.2 million from June
Operating profit rose to $25.1 million, or 7.0% of revenue, up 5.6 percentage points from a year ago. That happened because research and development fell 18.0 percentage points of revenue and selling and administrative costs fell 17.5 percentage points as sales grew. However, the $111.0 million ST-920 upfront charge and $19.3 million debt payoff loss pushed the bottom line to a $51.7 million net loss, while the $2.31 billion royalty liability keeps generating non-cash interest.
What to watch: operating cash flow in the third-quarter 10-Q filing. A positive figure excluding the $50 million second-quarter Novartis milestone would show whether everyday drug sales truly cover cash expenses.
Revenue Per Sephience Patient Fell Again
PTC tracks worldwide active patients on Sephience as its main indicator of demand. Active patients passed 2,000 at the end of September, up at least 21.4% from 1,647 in June. However, Sephience revenue grew 20.2% over the same three months to $181.9 million, continuing a gap where patient counts rise faster than sales.
By our math, revenue per average active patient slipped to about $100,000 this quarter, down from roughly $105,000 in the second quarter, $114,000 in the first quarter and $144,000 late last year. That drop reflects two forces: higher commercial rebates in the US and a bigger share of patients outside the US, where revenue rose to 20.3% of the product total from 15.7% last quarter.
What to watch: German reimbursement terms, which management previously expected in the second half of 2026. Because France, Italy, Spain and Brazil reference the German price, a steep discount there would pull revenue per patient down further in 2027.
Old Muscular Dystrophy Drugs Rely on Tenders
Before Sephience, the company depended on two medicines for Duchenne muscular dystrophy: Emflaza in the US and Translarna overseas. Emflaza lost its last orphan-drug protection in June 2026, and cheap generic copies are taking its patients. Emflaza sales dropped 28.7% from a year ago to $25.1 million.
Translarna lacks full European marketing approval and relies on country-by-country special access and lumpy state shipments. Its revenue edged down 4.3% from a year ago to $48.5 million, held up for a second straight quarter by "a government purchase order from Russia". Without bulk tenders from Russia or Brazil, underlying demand is much smaller.
What to watch: country-level product sales in the quarterly 10-Q filing. That table will show how much Russia contributed this quarter and how little regular Translarna revenue remains.
Risks this quarter didn't answer
Several standing concerns around patient retention, US demand and European pricing were not addressed in the earnings release.
- US patient start forms and US active patients: omitted for a second quarter after management retired the monthly start-form count in August.
- Sephience discontinuation rate: not mentioned in the release after rising to about 20% on last quarter's call; the conference call Q&A is the next check.
- German pricing and reimbursement decision: no update in the release on the agreement that sets reference prices across Europe and Brazil.
👓 Other Themes
FDA Scheduling Pushes Huntington's Meeting to 2027
PTC and partner Novartis had planned to meet the FDA in the second half of 2026 to discuss two-year data from the mid-stage PIVOT-HD trial of votoplam in Huntington's disease. "Due to FDA scheduling, Type C meeting to discuss votoplam Phase 2 data and potential accelerated approval path now scheduled for Q1 2027", the company said. The delay stems from agency calendar limits rather than trial problems.
💲 Other KPIs
Total debt fell by $54.7 million from June to $536.3 million, though it stays above the $286.6 million balance at the end of 2025. After issuing $550 million of zero-interest notes due in 2031 in June, the drugmaker cleared its remaining September 2026 convertible notes this quarter and booked a $19.3 million debt-payoff loss.
Diluted shares dropped 4.2% from a year ago and 9.3% from last quarter's 92.0 million. That drop is an accounting quirk: because the ST-920 charge created a net loss, accounting rules exclude employee stock options and convertible notes from the diluted count. Basic shares actually rose 6.4% from a year ago on employee stock grants.
🔮 Guidance
Raised. Management lifted the middle of the product sales plan by $75 million, to 66.2% growth over 2025. By our math, that leaves $234.7 million for Q4, down 14.9% from Q3 but up 27.6% from a year ago. It is the third raise this year: +$50M, +$100M, +$75M. The lower Q4 figure reflects lumpy Russia Translarna orders and caution on Sephience.
Raised. The company increased the middle of the range by $75 million, matching the product raise. Headline total revenue is set to fall 24.6% from 2025 because last year included a $1.0 billion upfront payment from Novartis; excluding collaboration revenue from 2025, the middle of the plan rises 78.2% by our math. That leaves $314.1 million for Q4, down 12.2% from Q3.
Unchanged. The group kept its combined research and administrative cost plan steady at a $795 million middle. Because nine-month spending sits at $552.3 million, the plan leaves $242.7 million for Q4 by our math, a 30.9% jump from Q3's $185.4 million as new trials for vatiquinone and PTC844 ramp up.
Unchanged. Excluding an estimated $95 million of stock-based pay, the operating cost plan stays at a $700 million middle. Nine-month spending of $481.7 million leaves $218.3 million for Q4 by our math, up 35.1% from Q3's $161.6 million. Last year the company finished below its cost range, so Q4 spending may not rise that steeply.
❓ Key Questions
What is the exact active patient count and US breakdown?
The release gave only a rounded figure of over 2,000 worldwide Sephience patients and omitted US start forms for a second quarter. Without the exact US and overseas split, investors cannot tell if US demand is slowing or if lower revenue per patient is purely international mix.
Where did the Sephience discontinuation rate land in Q3?
On last quarter's call, management said about 20% of patients had stopped taking Sephience, up from low double digits three months earlier. Now that the earliest US patients have been on the drug for a full year, whether drop-offs levelled off is critical.
How big was the Russian government order for Translarna?
Translarna generated $48.5 million in Q3, up from $42.2 million in Q2, because of another Russian state purchase order. In Q2, Russia accounted for $25.6 million of the total; knowing the Q3 tender size shows the true underlying run rate.
When will German Sephience pricing talks conclude?
Management previously expected German reimbursement decisions in the third or fourth quarter of 2026. Because early-access sales in France, Italy, Spain and Brazil reference the German price, the final rebate there sets 2027 international revenue.